The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...

The most common adverse reactions reported with treatment were conjunctival hemorrhage, delayed dark adaptation, foreign body sensation, eye pain, suture related complications, miosis ...

ENCELTO is the First and Only FDA-approved Treatment for MacTel. CUMBERLAND, RI, USA I March 06, 2025 I Neurotech Pharmaceuticals, Inc., a private biotech company focused on d ...

The surgical site should be examined closely and the ENCELTO should be surgically repositioned if indicated. The most common adverse reactions (incidence ≥2%) were conjunctival hemorrhage, delayed ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Across the GATHER clinical trial programme, the most common adverse reactions reported with Izervay at 12 months were conjunctival haemorrhage (13%), raised intraocular pressure (9%), and blurred ...

Interleukin-27 (IL-27) is a member of the IL-12 family. The gene encoding IL-27 is located at chromosome 16p11. IL-27 is considered as a heterodimeric cytokine, which consists of Epstein–Barr virus ...

Systemic manifestations of gnathostomiasis can affect the skin, brain, gastrointestinal tract and respiratory system, while ocular involvement is rare. 5 Intraocular gnathostomiasis, though uncommon, ...

Emil C Reisinger is a Full Professor of Medicine, Chairman of the Department of Internal Medicine, Infectious Diseases and Tropical Medicine and Dean of Students Affairs at Rostock University ...